GlassScriptPhysician profile
Irene Curry
NPI 1801205471
$2,166.67
in general payments reported to CMS, 2019-2025
21 companies · $866 in 2025
The $866 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $196 · 2023: $258 · 2024: $723 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Education: $10.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.51 |
| Education | $10.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $525.25 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $486.63 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $241.70 | 2024-2025 | |
| Boston Scientific Corporation | $138.07 | 2023-2025 | General - Vascular Intervention |
| E.R. Squibb & Sons, L.L.C. | $117.93 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $94.59 | 2021 | |
| Neurocrine Biosciences, INC. | $89.74 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $73.75 | 2023-2024 | Abilify Maintena, Abilify Mycite, Abilify Asimtufii |
| Viiv Healthcare Company | $60.66 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.94 | 2022-2024 | Caplyta |
| Indivior INC. | $52.20 | 2023-2024 | Perseris |
| Gilead Sciences, INC. | $51.60 | 2021-2022 | |
| Lundbeck LLC | $39.19 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $30.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.79 | 2025 | Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.72 | 2024 | Rybelsus, Ozempic |
| Intra-Sana Laboratories | $16.71 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Janssen Biotech, INC. | $15.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2023 | Trintellix |
| Almatica Pharma LLC | $14.42 | 2023 | Loreev Xr |
| Dexcom, INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.